Adct-301

Other Medications

EU Experimental ES med_spain_not_available 1 Clinical Trials

Description

Adct-301 is an investigational medicine being studied by ADC Therapeutics S.A. It is currently in Phase 1 clinical trials for certain advanced solid tumors, including colorectal cancer. This trial is designed to determine the safety and how well the drug is tolerated at different doses (Phase 1a) and to see if it has any activity against the cancer (Phase 1b). The trial combines Adct-301 with pembrolizumab, an immunotherapy drug. The study includes patients with different types of colorectal cancer, including those with MSI-H (microsatellite instability-high) and MSS (microsatellite stable) tumors, and those with varying levels of PD-L1 expression. Adct-301 is not yet approved for treating colorectal cancer.

Mechanism of Action

Adct-301 is being investigated as a potential treatment for certain cancers. The specific way it works (its mechanism of action) is being studied in clinical trials. It is designed to target cancer cells.

Side Effects

Because Adct-301 is still in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. Information about side effects from these early trials is typically focused on safety and tolerability at different doses. More detailed information on common and serious side effects will become available as the drug progresses through later stages of testing.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03621982 med_phase_prefix1
Archived
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
United States, Belgium, United Kingdom

Quick Info

CategoryOther Medications
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
767 trials
Leucovorin
Other Medications
625 trials
Trifluridine
Other Medications
44 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.